Hetero Drugs is an Indian pharmaceutical company headquartered in Hyderabad, Telangana. It is among the largest producers of active pharmaceutical ingredients (APIs) in India and is known globally for its generic antiretroviral (ARV) medicines used in the treatment of HIV/AIDS. The company operates manufacturing and research facilities across India and supplies medicines to several countries through generic and licensed-generic arrangements.
| Type | Private pharmaceutical company |
|---|---|
| Industry | Pharmaceuticals |
| Headquarters | Hyderabad, Telangana, India |
| Country | India |
| Products | Active pharmaceutical ingredients (APIs), finished dosage formulations, generics, biosimilars |
| Key therapeutic areas | Antiretrovirals, oncology, cardiovascular, anti-infectives, neurology |
Hetero began as an API manufacturer and gradually expanded into finished dosage forms, branded generics, and biosimilars. The group is structured around several entities, with Hetero Drugs Limited focused on APIs and Hetero Labs Limited focused on formulations. Over time the company has built a vertically integrated model, producing both bulk drug substances and the corresponding finished products.
Hetero is widely recognised for its role in supplying low-cost generic antiretroviral therapy for HIV/AIDS patients, particularly in low- and middle-income countries. The company has entered into voluntary licensing arrangements with originator pharmaceutical firms and the Medicines Patent Pool to manufacture and distribute generic versions of patented ARVs. Its ARV products have been procured by international agencies and national health programmes for treatment scale-up in Africa, Asia, and Latin America.
During the COVID-19 pandemic, Hetero entered into a licensing agreement with Gilead Sciences to manufacture and market generic versions of remdesivir in India and other designated countries. The company supplied the medicine under the brand name Covifor. Hetero was also among the Indian manufacturers involved in producing generic versions of the oral antiviral molnupiravir following voluntary licensing arrangements.
Hetero operates multiple manufacturing facilities in India, including units in Telangana, Andhra Pradesh, Himachal Pradesh, and other states. Its plants produce APIs, oral solid dosages, injectables, and biosimilar products. Several of its facilities have been inspected and approved by international regulators such as the United States Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and the World Health Organization (WHO) prequalification programme.
Hetero is regarded as part of the cohort of Indian generic manufacturers that have contributed to global access to affordable medicines, particularly in HIV treatment. Through voluntary licences and partnerships with global health organisations, the company has been involved in expanding the availability of treatments for infectious diseases in resource-limited settings.